Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Jim Cramer sees signs of market health, despite doomsday Wall Street whispers. He marvels at how various overlooked ...

MEPS is part of a largely hidden infrastructure of government statistics collection now in the crosshairs of the Department ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

Cardinal Health's stock has surged 133% since May 2022, but its long-term chart reveals a history of prolonged correction.

“GLP-1 medications have made a transformative impact in the obesity care space,” said Joseph Nadglowski, President and CEO of the OAC. “As these medicines continue to grow in ...

“Just look at GLP-1 prices. One drug, which costs $900 in the U.S., costs about a tenth of that in Europe.” From an employer’s perspective, the high costs and low adherence rates of GLP-1s ...

The 30-track project not only marks his first chart-topper in Australia, but also his first entry into the ARIA top 10. By Jessica Lynch Playboi Carti has landed his first-ever No. 1 on the ARIA ...

In previous GLP toxicology studies and Phase 1 studies conducted by Amgen and ... BioAge had approximately $354.3 million in cash and cash equivalents. Based on our current operating plan, BioAge ...

All patients remained adherent to the GLP-1 medication through 8 months. "I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages," said Dr. Luigi Flagiello ...

Dose expansion in Phase 1 CARDINAL trial ... the potential of GLP-1 agonist/GIPR antagonist combinations for obesity Cash Position: As of December 31, 2024, cash, cash equivalents and marketable ...